<DOC>
	<DOCNO>NCT02600715</DOCNO>
	<brief_summary>The purpose study test whether use belladonna &amp; opiate suppository ( B &amp; Os ) improve patient discomfort Onabotulinumtoxin A ( BoNT ) injection bladder treatment overactive bladder , neurogenic detrusor overactivity , interstitial cystitis .</brief_summary>
	<brief_title>Reduction Bladder Injection Pain With Belladonna Opiate Suppository</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Cystitis , Interstitial</mesh_term>
	<mesh_term>Urinary Incontinence , Urge</mesh_term>
	<mesh_term>Urinary Bladder , Neurogenic</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Met clinical criterion outside care Principal Investigator 's routine standard care BoNT injection therapy No contraindication BoNT therapy outline drug manufacturer guideline Participants elect BoNT injection therapy prior offer enrollment study either overactive bladder ( OAB ) , neurogenic detrusor overactivity ( NDO ) , refractory interstitial cystitis ( IC ) Currently pregnant Currently nurse baby Anticipated geographic relocation within first 3 month follow treatment Allergy morphine , belladonna , opiates Patients exclude participate another research study Individuals unable provide inform consent complete twoweek followup bladder test ( postvoid residual ) data collection also exclude</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>